MBL Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

MBL Wealth’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-480	Closed	-$371K	–	406
2026 Q1	$371K	Buy	+480	New	+$367K	0.03%	231

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

MBL Wealth's REGN Position: Q2 2026 in Review

MBL Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 480 shares — an estimated $371K sold.

MBL Wealth first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $371K in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

MBL Wealth reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
MBL Wealth sold 480 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $371K.
MBL Wealth first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
MBL Wealth's Regeneron Pharmaceuticals position peaked at $371K in Q1 2026.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on MBL Wealth's 13F filing for Q2 2026, filed 15 Jul 2026.